论文部分内容阅读
目的评价格列吡嗪两种剂型治疗2型糖尿病的成本-效果。方法经患者知情同意,60例2型糖尿病患者随机分为2组,分别服用格列吡嗪控释片和普通片,以为期12周的疗效观察结合药品成本评价药物的成本-效果。结果治疗12周普通片组与控释片组患者均达到理想的血糖控制效果,且与治疗前相比,治疗后空腹血糖分别下降26%和28%,餐后2 h血糖分别下降38%和36%,糖化血红蛋白分别下降23%和24%,上述指标组间差异无统计学意义,但两组成本-效果分析显示组间差异显著,普通片组成本-效果低于控释片组(P<0.05),然而控释片组服药依从性好。结论格列吡嗪普通片具有成本优势,控释片服药依从性好,两者长期用药的成本-效果评价尚待进一步研究。
Objective To evaluate the cost-effectiveness of glipizide in the treatment of type 2 diabetes mellitus. Methods Sixty patients with type 2 diabetes mellitus were randomly divided into two groups. Patients were treated with glipizide controlled-release tablets and common tablets respectively. The cost-effectiveness of the drugs was evaluated by 12-week observation of efficacy and drug cost. Results In the 12-week treatment group, both the normal group and the controlled-release group achieved the ideal blood glucose control effect. Compared with before treatment, the fasting blood glucose decreased by 26% and 28% respectively, and the blood glucose decreased by 38% 36% and HbA1c decreased by 23% and 24% respectively. There was no significant difference between the two groups. However, the cost-effectiveness analysis of the two groups showed significant difference between the two groups <0.05), however, the controlled release tablets group had good compliance. Conclusion The conventional glipizide tablets have the advantages of cost advantage and controlled release tablets, and the long-term cost-effectiveness evaluation of the two drugs remains to be further studied.